Key facts
- Notable investors include Zhenji Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Cullinan Biopharmaceutical Technology (Hangzhou)
- ·The full record, as it builds
Funding rounds
No funding rounds for Cullinan Biopharmaceutical Technology (Hangzhou) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cullinan Biopharmaceutical Technology (Hangzhou)
Developer of biopharmaceutical innovation techniques designed to accelerate drug discovery and enhance therapeutic efficacy. The company offers cutting-edge molecular engineering, robust clinical validation, scalable production capabilities, and stringent quality assurance, enabling pharmaceutical developers and healthcare institutions to access advanced treatments that improve patient outcomes and streamline development processes.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
Cullinan Biopharmaceutical Technology (Hangzhou) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cullinan Biopharmaceutical Technology (Hangzhou) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cullinan Biopharmaceutical Technology (Hangzhou) in its N-PORT filings yet. We sweep new filings monthly.